Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 14/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554431 | 0.86 | HDAC2 (0.56) | HDAC2HDAC1HDAC3 | |
| SCHEMBL3549014 | 0.80 | HDAC2 (0.59) | HDAC2HDAC1HDAC3 | |
| SCHEMBL3554578 | 0.79 | HDAC1 (0.47) | HDAC2HDAC1HDAC3 | |
| SCHEMBL16083172 | 0.76 | HDAC2 (1.00) | HDAC2HDAC1HDAC3EPHX2PPARG | |
| SCHEMBL3550698 | 0.74 | HDAC1 (0.58) | HDAC2HDAC1 | |
| SCHEMBL3554525 | 0.74 | HDAC2 (0.58) | HDAC2HDAC1HDAC3 | |
| SCHEMBL16083164 | 0.74 | HDAC2 (0.79) | HDAC2HDAC1HDAC3 | |
| SCHEMBL3552621 | 0.73 | HDAC1 (0.59) | HDAC2HDAC1 | |
| SCHEMBL3551812 | 0.73 | HDAC1 (0.52) | HDAC2HDAC1HDAC3 | |
| SCHEMBL3558093 | 0.72 | HDAC2 (0.52) | HDAC2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | claimed |
| CN-101263121-A | Histone deacetylase inhibitors | TAKEDA SAN DIEGO INC (US) | 2008-09-10 | — | — | CN | claimed |
| EP-1904452-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | claimed |
| US-7741494-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741494-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732475-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20090111996-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111996-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105485-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-08 | — | — | US | disclosed |
| EP-1904452-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011626-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015809-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC2 4/4885HDAC1 1/4885HDAC3 2/4885 |
| US-20080108829-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC2 4/4885HDAC1 1/4885HDAC3 2/4885 |
| US-20090105485-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC2 4/4885HDAC1 1/4885HDAC3 2/4885 |
| US-20090111996-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC5 | HDAC2 4/4885HDAC1 1/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.